June 9, 2026 · The Journal of allergy and clinical immunology · DOI: 10.1016/j.jaci.2026.05.023

Antigen-Specific mRNA-LNP Therapy with mTOR Inhibition Promotes Treg Cells and Limits Allergy

Listen to this summary

The authors investigate whether combining an allergen-encoded mRNA-lipid nanoparticle (mRNA-LNP) vaccine with an mTOR inhibitor can enhance regulatory T-cell responses and improve immune tolerance in allergic diseases. Their findings indicate that this combination effectively promotes the generation of regulatory T cells, reduces Th2 responses, and limits allergic symptoms in a preclinical model of asthma. This approach suggests a promising strategy for enhancing regulatory immunity in allergy treatment.

Yrina Rochman, Jilian R Melamed, Andrea M Klingler, Michael Kotliar, Mark Rochman, Julie M Caldwell, Jennifer M Felton, Garrett A Osswald, Jenna Muscat-Rivera, Michael Kegel, Artem Barski, Ian P Lewkowich, Drew Weissman, Marc E Rothenberg

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play